AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24283167 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid Anesthesia (SA)
Number of subjects: 380
Study 21533657 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioguided seed localization (RSL)
Number of subjects: 305
Study 21533657 — intervention group
Group type: COMPARATOR
Intervention: Wire localization (WL)
Number of subjects: 305
Study 18281407 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPPS plus treatment as usual
Number of subjects: 124
Study 18281407 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual alone
Number of subjects: 124
Study 16537679 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (MET)
Number of subjects: 13
Study 16537679 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (MET) + Oral Hydrocortisone
Number of subjects: 13
Study 16537679 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 13
Study 16537679 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding condition (FED)
Number of subjects: 13
Study 16537679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting condition (FAST)
Number of subjects: 13
Study 12205648 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (up to 80mg daily)
Number of subjects: 44
Study 12205648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10353378 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hand
Number of subjects: 18
Study 10353378 — intervention group
Group type: COMPARATOR
Intervention: Left hand
Number of subjects: 18
Study 7866800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo/Cuff
Number of subjects: 102
Study 7866800 — intervention group
Group type: COMPARATOR
Intervention: Ice and elastic wrap
Number of subjects: 102
Study 16296700 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg daily
Number of subjects: 0
Study 16296700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7142740 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid formulated in a series of solutions and gels at 90% saturation
Number of subjects: 0
Study 30975584 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆9-tetrahydrocannabinol (THC)
Number of subjects: 39
Study 28711318 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided therapy
Number of subjects: 1710
Study 28711318 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1710
Study 25944854 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg)
Number of subjects: 303
Study 25944854 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan (80 mg)
Number of subjects: 303
Study 24338254 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone and Vitamin E (50mg/day)
Number of subjects: 240
Study 24338254 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone plus placebo
Number of subjects: 240
Study 22884593 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 20399
Study 22884593 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 20399
Study 22884593 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 20399
Study 22884593 — intervention group
Group type: COMPARATOR
Intervention: Boys
Number of subjects: 20399
Study 19552659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use fortified spread
Number of subjects: 336
Study 19552659 — intervention group
Group type: COMPARATOR
Intervention: Corn/soy blended flour
Number of subjects: 336
Study 17428017 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg gabapentin capsule
Number of subjects: 24
Study 15682770 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans (AA)
Number of subjects: 3204
Study 15682770 — intervention group
Group type: COMPARATOR
Intervention: Caucasians (C)
Number of subjects: 3204
Study 11462061 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 8
Study 11462061 — intervention group
Group type: EXPERIMENTAL
Intervention: D-arginine
Number of subjects: 8
Study 11462061 — intervention group
Group type: COMPARATOR
Intervention: 2.0% saline
Number of subjects: 8
Study 9160940 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis inserted without cement
Number of subjects: 139
Study 9160940 — intervention group
Group type: COMPARATOR
Intervention: Prosthesis inserted with cement
Number of subjects: 139
Study 7965151 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-123-MIBG SPECT
Number of subjects: 25
Study 7965151 — intervention group
Group type: COMPARATOR
Intervention: Planar imaging
Number of subjects: 25
Study 7965151 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar and SPECT combined
Number of subjects: 25
Study 3602221 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ECT two times weekly
Number of subjects: 20
Study 3602221 — intervention group
Group type: COMPARATOR
Intervention: Unilateral ECT three times weekly
Number of subjects: 20
Study 31808136 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ICH OAC use
Number of subjects: 1502
Study 30740964 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral medroxyprogesterone acetate (MPA) 500 mg/day / levonorgestrel-intrauterine system (LNG-IUS)
Number of subjects: 44
Study 30740964 — intervention group
Group type: COMPARATOR
Intervention: Endometrial aspiration biopsy
Number of subjects: 44
Study 30740964 — intervention group
Group type: COMPARATOR
Intervention: Dilatation & curettage (D&C)
Number of subjects: 44
Study 28405743 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional technique for Pap smear (41 women)
Number of subjects: 81
Study 28405743 — intervention group
Group type: COMPARATOR
Intervention: Liquid-based cytology (40 women)
Number of subjects: 81
Study 28405743 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer variability among cytopathologists
Number of subjects: 81
Study 24759040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (23-28 en% protein)
Number of subjects: 420
Study 24759040 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein control diet (10-15 en% protein)
Number of subjects: 420
Study 24759040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (23-28 en% protein) in (pre)hypertensive subjects
Number of subjects: 420
Study 24759040 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein control diet (10-15 en% protein) in (pre)hypertensive subjects
Number of subjects: 420
Study 24759040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (23-28 en% protein) after adjustment for initial BP
Number of subjects: 420
Study 24759040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (23-28 en% protein) after adjustment for weight change
Number of subjects: 420
Study 23399553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 440 mcg twice daily
Number of subjects: 42
Study 23399553 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 42
Study 20574056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 24
Study 20574056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20574056 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep measures
Number of subjects: 24
Study 19514651 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin 0.1 mg)
Number of subjects: 40
Study 19514651 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist (cetrorelix 0.25 mg)
Number of subjects: 40
Study 16741040 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 29
Study 16741040 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 29
Study 16741040 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 29
Study 16741040 — intervention group
Group type: COMPARATOR
Intervention: Control (age- and sex-matched normal subjects)
Number of subjects: 29
Study 15578258 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine
Number of subjects: 12
Study 15578258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 12
Study 15578258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 12
Study 15578258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10940698 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (100 mg/m² i.v.) every 3 weeks plus medroxy progesterone acetate (MPA) 500 mg orally twice daily
Number of subjects: 26
Study 10940698 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin alone
Number of subjects: 26
Study 9051395 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric biphasic stimulation (A)
Number of subjects: 80
Study 9051395 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric biphasic stimulation (B)
Number of subjects: 80
Study 9051395 — intervention group
Group type: COMPARATOR
Intervention: Control group (very low levels of stimulation current (MC) and no electrical stimulation (C))
Number of subjects: 80
Study 8335504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg for one day
Number of subjects: 195
Study 8335504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg for two days
Number of subjects: 195
Study 8335504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 8335504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (both regimens)
Number of subjects: 195
Study 3720211 — intervention group
Group type: EXPERIMENTAL
Intervention: Minibag group (50- and 100-mL minibags of 5% dextrose injection or 0.9% sodium chloride injection)
Number of subjects: 93
Study 3720211 — intervention group
Group type: COMPARATOR
Intervention: Syringe group (20- and 50-mL quantities of sterile water for injection or 0.45% sodium chloride injection in plastic syringes)
Number of subjects: 93
Study 3341253 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction intervention (average loss of 12.3 kg)
Number of subjects: 68
Study 3341253 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction intervention
Number of subjects: 68
Study 30962676 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973
Number of subjects: 44
Study 30962676 — intervention group
Group type: COMPARATOR
Intervention: rFVIII-FS
Number of subjects: 44
Study 30962676 — intervention group
Group type: COMPARATOR
Intervention: rAHF-PFM
Number of subjects: 44
Study 28850308 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 250 mg twice daily
Number of subjects: 36
Study 28850308 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 500 mg twice daily
Number of subjects: 36
Study 28850308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25346376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pillar implant
Number of subjects: 29
Study 24139250 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 2% lidocaine with 1:100,000 epinephrine (buffered with 0.18 mL 8.4% sodium bicarbonate)
Number of subjects: 81
Study 24139250 — intervention group
Group type: COMPARATOR
Intervention: Nonbuffered 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 81
Study 21655195 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 71
Study 21655195 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 71
Study 21655195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both men and women
Number of subjects: 71
Study 19536884 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐3512676 40 mg + DTIC (850 mg/m(2))
Number of subjects: 184
Study 19536884 — intervention group
Group type: COMPARATOR
Intervention: DTIC (850 mg/m(2)) alone
Number of subjects: 184
Study 19536884 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐3512676 10 mg
Number of subjects: 184
Study 19536884 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐3512676 40 mg
Number of subjects: 184
Study 16770284 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 kcal daily intravenous supplement for 3 days, followed by a 400 kcal oral nutritional supplement for 7 days
Number of subjects: 80
Study 16770284 — intervention group
Group type: COMPARATOR
Intervention: Ordinary hospital food and beverage
Number of subjects: 80
Study 15316335 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐INF + RBV
Number of subjects: 95
Study 15316335 — intervention group
Group type: COMPARATOR
Intervention: INF + RBV
Number of subjects: 95
Study 15316335 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 95
Study 11535845 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with a mixture of bupivacaine and fentanyl
Number of subjects: 42
Study 11535845 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with intravenous morphine
Number of subjects: 42
Study 9433593 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint linkage analysis using highly deviant concordant and discordant independent sib pairs
Number of subjects: 0
Study 9433593 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage analysis on adjusted quantitative variables
Number of subjects: 0
Study 8300887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 109
Study 8300887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 109
Study 8300887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 109
Study 8300887 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 109
Study 2882083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant ('Surfactant TA') 100 mg/kg surfactant phospholipid
Number of subjects: 30
Study 2882083 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 2882083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant ('Surfactant TA')
Number of subjects: 30
Study 28549161 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Innovative System Intervention (E‐ISI)
Number of subjects: 175
Study 28549161 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment Control (STC)
Number of subjects: 175
Study 26872889 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir and asunaprevir
Number of subjects: 28
Study 26872889 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without renal dysfunction)
Number of subjects: 28
Study 25130401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiliximab in combination with fludarabine, cyclophosphamide and rituximab (FCR)
Number of subjects: 627
Study 25130401 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine, cyclophosphamide and rituximab (FCR) alone
Number of subjects: 627
Study 22533481 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-coached group (DC)
Number of subjects: 101
Study 22533481 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 101
Study 19557400 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved quality of discharge summary with clinical pharmacists reviewing and providing feedback on the medication report before discharge.
Number of subjects: 115
Study 19557400 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard discharge summary process.
Number of subjects: 115
Study 19557400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with improved discharge summary process.
Number of subjects: 115
Study 19557400 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients using the ApoDos medication dispensing system.
Number of subjects: 115
Study 17720113 — intervention group
Group type: COMPARATOR
Intervention: Through-the-needle (TTN) injection
Number of subjects: 80
Study 17720113 — intervention group
Group type: EXPERIMENTAL
Intervention: Through-the-catheter (TTC) anesthesia
Number of subjects: 80
Study 16344052 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided polyp detection (CAD) program
Number of subjects: 1186
Study 16344052 — intervention group
Group type: COMPARATOR
Intervention: Optical colonoscopy
Number of subjects: 1186
Study 12269719 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) with electrical stimulation at 4 pulses/second for 20 minutes, 6 treatments over 2 weeks
Number of subjects: 20
Study 12269719 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture (MA) with needle retained for 20 minutes after Deqi sensation, 6 treatments over 2 weeks
Number of subjects: 20
Study 10204815 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockade (atenolol, metoprolol, pindolol, propranolol)
Number of subjects: 35
Study 10204815 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockade
Number of subjects: 35
Study 7554521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) 5 mg/kg/day and prednisolone 10 mg/day for up to 8 months
Number of subjects: 30
Study 2405113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed self-care pamphlet for URI care
Number of subjects: 20127
Study 2405113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pamphlet)
Number of subjects: 20127
Study 2405113 — intervention group
Group type: COMPARATOR
Intervention: All patients (experimental and control)
Number of subjects: 20127
Study 7025715 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 8
Study 28862032 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin pre-treatment
Number of subjects: 7144
Study 28862032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin pre-treatment)
Number of subjects: 7144
Study 28160513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pru p 3 sublingual immunotherapy (SLIT)
Number of subjects: 48
Study 28160513 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 48
Study 26586494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 71
Study 26586494 — intervention group
Group type: COMPARATOR
Intervention: Fatigue education and support (ES)
Number of subjects: 71
Study 25516024 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression intervention (up to 10 one-hour sessions over 4 months)
Number of subjects: 208
Study 25516024 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression intervention
Number of subjects: 208
Study 22959984 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV0
Number of subjects: 342
Study 22959984 — intervention group
Group type: COMPARATOR
Intervention: No OPV0
Number of subjects: 342
Study 22959984 — intervention group
Group type: COMPARATOR
Intervention: No OPV0 (boys)
Number of subjects: 342
Study 19293594 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured as steps/day) in HD patients
Number of subjects: 61
Study 19293594 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured as steps/day) in PD patients
Number of subjects: 61
Study 19293594 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest category of steps/day in HD patients
Number of subjects: 61
Study 19293594 — intervention group
Group type: COMPARATOR
Intervention: Physical activity in PD patients
Number of subjects: 61
Study 17853636 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 0
Study 17853636 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (MBP)
Number of subjects: 0
Study 17853636 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 15266338 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agent carboplatin
Number of subjects: 361
Study 15266338 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-based combinations
Number of subjects: 361
Study 11372583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous indomethacin (10 micrograms/ml and 100 micrograms/ml)
Number of subjects: 51
Study 11372583 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral indomethacin (100 mg)
Number of subjects: 51
Study 11372583 — intervention group
Group type: COMPARATOR
Intervention: Mepyramine (10 micrograms/ml)
Number of subjects: 51
Study 11372583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous NDGA
Number of subjects: 51
Study 11372583 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral zafirlukast (40 mg)
Number of subjects: 51
Study 9844453 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/12 h) + Clarithromycin (500 mg/12 h) + Metronidazole (500 mg/12 h)
Number of subjects: 48
Study 9844453 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg/12 h) + Clarithromycin (500 mg/12 h) + Amoxicillin (1 g/12 h)
Number of subjects: 48
Study 7862925 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP) 0.4 mg/kg
Number of subjects: 12
Study 7862925 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 2510267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms b.d.
Number of subjects: 156
Study 2510267 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg b.d.
Number of subjects: 156
Study 2510267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil and Ranitidine
Number of subjects: 156
Study 1099445 — intervention group
Group type: EXPERIMENTAL
Intervention: 17alpha-hydroxyprogesterone caproate
Number of subjects: 43
Study 1099445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31242892 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (12 sessions of 90 min, once a week led by two Primary Care nurses)
Number of subjects: 504
Study 31242892 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 504
Study 28582808 — intervention group
Group type: EXPERIMENTAL
Intervention: A. muricata leaf extract
Number of subjects: 30
Study 28582808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25925487 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention protocol for pelvic floor muscle training (30 min, twice a week, total of 10 sessions)
Number of subjects: 46
Study 24033725 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-driven (FD) device (RM3; Waters Medical Inc)
Number of subjects: 50